Table 18 Top 10 pairs of drugs with their correlation with subtype 6 of breast cancer, considering both combined and individually
From: Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Drug1 | Drug2 | C. Cor. | Cor. 1 | Cor. 2 | C. Rank | Rank 1 | Rank 2 |
|---|---|---|---|---|---|---|---|
Ruxolitinib | Bitopertin | − 0.73 | − 0.67 | − 0.40 | 1 | 1 | 44 |
Raclopride | Bitopertin | − 0.72 | − 0.41 | − 0.40 | 2 | 36 | 44 |
Maraviroc | Tadalafil | − 0.70 | − 0.49 | − 0.43 | 3 | 3 | 23 |
Favipiravir | L-690330 | − 0.70 | − 0.45 | − 0.42 | 4 | 13 | 32 |
Ruxolitinib | MG-132 | − 0.68 | − 0.67 | − 0.38 | 5 | 1 | 55 |
Rupatadine | Bitopertin | − 0.67 | − 0.50 | − 0.40 | 6 | 2 | 44 |
Maraviroc | Bitopertin | − 0.66 | − 0.49 | − 0.40 | 7 | 3 | 44 |
Raclopride | Cevimeline | − 0.66 | − 0.41 | − 0.36 | 8 | 36 | 74 |
Deferiprone | Racecadotril | − 0.66 | − 0.49 | − 0.48 | 9 | 4 | 8 |
Rupatadine | Deferiprone | − 0.66 | − 0.50 | − 0.49 | 10 | 2 | 4 |